{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "EU ORPHAN DRUG|Positive" in comments (approximate match)
Status:
Investigational
Source:
NCT02137343: Phase 3 Interventional Terminated Gastric Cancer
(2014)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03736447: Phase 3 Interventional Completed Peanut Allergy
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00877656: Phase 2/Phase 3 Interventional Completed T Cell Lymphoma
(2005)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01101581: Phase 1/Phase 2 Interventional Withdrawn Non Hodgkin's Lymphoma
(2010)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00989586: Phase 1/Phase 2 Interventional Completed Lymphoma
(2009)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
USAN:PROINSULIN HUMAN [USAN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00738582: Phase 2 Interventional Completed Malignant Pleural Mesothelioma
(2008)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00031733: Phase 2 Interventional Completed Intraocular Melanoma
(2002)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01665391: Phase 2 Interventional Completed Primary Focal Segmental Glomerulosclerosis
(2012)
Source URL:
Class:
PROTEIN
Status:
Designated
Source:
EU-Orphan Drug:EU/3/15/1492
Source URL:
Class:
PROTEIN
